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Abstract: Intravenous immunoglobulins (IVIg) have been shown in a number of trials, to be an effective treatment for the 
three main types of inflammatory neuropathies: Guillain-Barré Syndrome (GBS), chronic inflammatory demyelinating 
polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is thought to exert its immunomodulatory effects 
by affecting several components of the immune system including B-cells, T-cells, macrophages, complement, cytokines 
and cellular adhesion molecules. This article reviews the published evidence and the principal postulated mechanisms of 
action of intravenous immunoglobulins with special emphasis on inflammatory neuropathies.  
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INTRODUCTION 
  Intravenous immunoglobulins (IVIg) have been shown to 
be  effective  in  a  number  of  disorders  with  an  underlying 
autoimmune  basis.  Amongst  those,  the  inflammatory  neu-
ropathies, Guillain-Barré Syndrome (GBS), chronic inflam-
matory demyelinating polyneuropathy (CIDP), and multifo-
cal motor neuropathy (MMN), have all been found in well-
conducted  randomised  controlled  trials  (RCTs)  to  benefit 
from IVIg.  
  GBS is an acute polyradiculoneuropathy which could be 
demyelinating (as in the “AIDP”, i.e. “Acute Inflammatory 
Demyelinating Polyneuropathy” variant) or axonal (as in the 
“AMAN”, i.e. “Acute Motor Axonal Neuropathy” variant). 
Its incidence is estimated at 1 to 2 per 100,000. Respiratory 
involvement is common, and mortality is estimated at about 
10%. Proximal and distal symmetric weakness with sensory 
symptoms but few sensory signs occur in the majority cases. 
Facial and bulbar weakness is not uncommon. Diagnosis is 
clinical but also relies on electrophysiology which may show 
signs  of  demyelination,  and  spinal  fluid  analysis  typically 
shows  a  raised  protein  level  with  normal  cellularity.  The 
syndrome occurs in a post-infectious context in 75% of cases 
and probably results from cross-reactivity with the infectious 
agent  and  peripheral  nerve  sharing  common  epitopes  to 
which  autoantibody  attack  is  directed.  The  most  common 
infectious agent resulting in GBS is Campylobacter jejuni. 
Plasma  exchanges  were  shown  to  be  more  effective  than 
placebo for GBS in RCTs [50]. IVIg was subsequently found 
to  be  of  equivalent  effectiveness  to  plasma  exchange  [27] 
and has become standard treatment for GBS because of ease 
of administration and a comparatively better side-effect pro-
file. 
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  CIDP  is  an  acquired  heterogeneous  disorder  affecting 
sensory and motor peripheral nerves caused by a patchy de-
myelinating  process,  producing  sensory  loss  and  positive  
sensory symptoms as well as motor weakness. Its prevalence 
is  of  3  to  5  per  100,000  and  incidence  of  about  0.50  per 
100,000/year. In its typical form, the disorder is symmetric 
and involves both proximal and distal  limb regions. There 
are rarer  atypical forms which  can produce predominantly 
uni- or multifocal as well as distal involvement. Diagnosis 
relies on clinical features, and also mainly on electrophysiol-
ogy, which allows demonstration of a demyelinating process, 
producing slowing of nerve conductions in various segments 
as  well  as  conduction  block.  Cerebrospinal  fluid  protein 
level is raised in the majority of cases, and peripheral nerve 
histology, may show a demyelinating process with inflam-
matory  features.  Magnetic  resonance  imaging  (MRI)  can 
show  thickened  hyperintense  nerve  roots,  trunks  or  plexi, 
consistent with the diagnosis. IVIg as well as steroids and 
plasma  exchanges  have  been  shown  to  be  effective  treat-
ments for CIDP. The pathogenesis of CIDP is inflammatory, 
most probably autoimmune, involving both T cells and anti-
bodies. The efficacy of IVIg in CIDP has been shown in dif-
ferent studies [26, 42]. 
  MMN is a rare disorder with an estimated prevalence of 
1 to 2 per 100,000 frequently occurring in middle-aged men. 
It  predominantly  affects  the  upper  limbs  with  asymmetric 
weakness occurring in individual nerve distributions. There 
is typically no sensory involvement. The diagnosis is clinical 
and confirmed in the majority of cases by electrophysiology 
which  shows  evidence  of  motor  conduction  block.  Anti-
GM1 antibody positivity  can be present  in 30 to 80 % of 
cases. IVIg is the only treatment so far, found effective in 
MMN [4, 19, 36, 66]. 
HISTORY  OF  USE  OF  INTRAVENOUS  IMMUNO-
GLOBULIN 
  The two main components of the adaptive immunity are 
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sponsible for cell-mediated immunity). Immune deficiencies 
occurring in either of the components have been shown to 
increase susceptibility to bacterial, viral or fungal infections. 
Antibody therapy had been recognised as a useful tool since 
the late 19
th century when von Behring described antibodies 
against diphtheria. Replacement of immunoglobulins, either 
subcutaneously or intravenously, has been described as  an 
effective therapy for primary immunodeficiencies for almost 
50 years [9, 10]. In 1981 it was observed that intravenous 
immunoglobulin (IVIg) therapy in children with hypogam-
maglobulinemia  and  coincidental  idiopathic  thrombocy-
topenic  purpura,  led  to  a  reproducible  increase  in  platelet 
count [29]. This led way to the use of IVIg in several other 
diseases with a confirmed or suspected autoimmune aetiol-
ogy.  
  Multiple sclerosis was one of the first neurological disor-
ders in which IVIg was used [56], although it is not currently 
recommended  by  many  guidelines.  Since  then,  several  re-
ports of the successful use of IVIg have been published in 
several neuromuscular diseases including myasthenia gravis 
(MG) [1, 16, 18], CIDP [72], Gullain-Barre syndrome [2, 32] 
and multifocal motor neuropathy [46].  
  Currently, the use of IVIg can be classified broadly into 
low dose replacement therapy (usually 0.3-0.5g/kg every 3-4 
weeks) or high-dose therapy for the anti-inflammatory action 
(usually 1-3g/kg). The comparison of IVIg dosing of 1.2g/kg 
over 3 days or 2.4 g/kg over 6 days in GBS has shown a bet-
ter outcome for the six-day regimen [49]. However in CIDP 
lower  initiating  and  maintenance  doses  may  be  sufficient 
[48], although large scale randomised trials looking into the 
exact dosing requirement are lacking. The half-life of IgG in 
the circulation is approximately 4 weeks, thereby requiring 
repeated courses every 8-12 weeks.  
MECHANISMS OF ACTION OF IVIg 
  Although the presence of “natural” antibodies capable of 
recognising foreign antigens could plausibly explain the role 
of IVIg in IgG replacement therapy, the precise mechanism 
of action by which IVIg exerts its immunomodulatory effects 
is not clearly understood. In inflammatory neuropathies there 
are several proposed pathophysiological mechanisms and a 
detailed review of these is beyond the scope of this article 
and has been dealt with elsewhere [25, 65, 67]. Pathological 
studies of nerve biopsies in CIDP and GBS reveal lympho-
cytic  and  macrophagic  infiltrates  in  the  endoneurium  with 
deposits of IgM and complement components. The role of B-
cells  is  clearly  established  in  GBS  where  anti-ganglioside 
antibodies  and  complement  activation  have  been  demon-
strated  [67].  Lymphocytic  infiltrates  are  predominantly  T-
cells recruited by chemokines and endothelial cell adhesion 
molecules.  T-cells  secrete  matrix  metalloproteases  which 
break down endoneurial proteins. Macrophages are the pre-
dominant  antigen  presenting  cells  as  demonstrated  by  in-
creased expression of NFκB and the inflammatory cytokines, 
IL-6 and IL-1β. All these mechanisms are potentially modu-
lated by IVIg and will be discussed in detail below. Para-
doxically, plasma exchange which works theoretically oppo-
site to IVIg by removing IgG from the body, seem to work in 
similar clinical situations.  
1. Effect of IVIg on B-Cells and Antibodies 
  B-cells, which form 5-15% of the circulating lymphoid 
pool, are responsible for humoral immunity and acts against 
extracellular pathogens. B-cells are activated in response to a 
variety  of  stimuli  and  differentiate  to  form  plasma  cells. 
Plasma cells are usually restricted to the secondary lymphoid 
organs,  comprising  less  than  0.1%  of  the  lymphocytes  in 
circulation. Autoreactive B-cells may be stimulated by either 
autoantigens or  through non-specific polyclonal  activation. 
Soluble  immunoglobulins,  produced  by  the  plasma  cells 
against  autoantigens,  are  responsible  for  the  majority  of 
clinical features in antibody mediated autoimmune diseases.  
  The use of IVIg in acquired haemophilia has shown that 
the  presence  of  anti-idiotype  antibodies  against  the  anti-
haemophilic factor (factor VIII antibodies) leads to a thera-
peutic  suppression  of  these  autoantibodies  [53,  61].  Anti-
idiotypes  against  autoantibodies  to  thyroglobulin  [17], 
ANCA [51], acetylcholine receptor [77], DNA [58], platelet 
glycoproteien  IIb/IIIa  [41],  beta-2  glycoprotein-I  [7]  and 
intrinsic factor [52] have been shown to be present in IVIg 
preparations.  The  presence  of  anti-idiotypes  prevents  the 
binding of pathogenic autoantibodies to the target epitopes, 
thereby  ameliorating  the  autoimmune  symptoms.  Anti-
idiotype antibodies are likely to be involved in the therapeu-
tic  effects  of  IVIg  in  GBS  and  MMN,  where  antibodies 
against different gangliosides have been described.  
  Other B-cell mediated effects of IVIg include inhibition 
of antibody production [33], inhibition of B-cell differentia-
tion [60],  inhibition of production of interleukin-6  and tu-
mour  necrosis  factor-α  [63],  induction  of  B-cell  apoptosis 
[64], down-regulation of specific auto-reactive B-cells [70] 
and  regulation  of  B-cell  subsets  expressing  CD5  [69], 
thereby suppressing the auto-antibody producing CD20+ B1 
cells. Even  though the serum  anti-GM1 antibody levels  in 
seropositive MMN patients do not fall after IVIg infusion, 
the Fab portion of Ig in the IVIg has been shown to inhibit 
binding of anti-GM1 Ab to  target antigens [39]. Although 
the efficacy of IVIg in IgM paraproteinemic neuropathies is 
not  well  established,  the  levels  of  IgM  myelin-associated
 
glycoprotein  (MAG)  and  sulfoglucuronyl  paragloboside 
(SGPG) antibodies are reduced in occasional patients treated 
with this therapy [15]. 
  FcRn  (so  named  because  it  was  initially  identified  in 
neonatal intestinal epithelium) is a protective receptor crucial 
for regulating the half life of IgG. In normal circumstances, 
IgG binds to FcRn  and is protected from catabolism  after 
being internalised in the endosome. IVIg is thought to satu-
rate  these  receptors  and  thus  accelerate  the  breakdown  of 
endogenous IgG which may be mediating the autoimmune 
repertoire [76]. IVIg has also been shown in experimental 
animals to modulate B-cell migration from bone marrow to 
secondary lymphoid organs [62].  
2. Effect of IVIg on T-Cells 
  T-cells mediate the cell mediated immunity and are in-
volved in  the handling of  intracellular pathogens, but also 
play a major role in the regulation of B-cell responses. This 
is mediated by the two sub-population of CD4+ T-cells or T-
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2)  and  interferon-γ  (IFN-γ)  protect  against  intracellular 
pathogens and Th2 cells secreting IL-4, IL-5, IL-6 and IL-10 
are effective in stimulating B-cells for antibody production. 
Th cells which normally fail to recognise auto-antigens can 
be primed by cross-reacting microbial molecules to recog-
nise autoantigens in organ specific epithelial cells to induce 
autoimmune disease. 
  In animal models of experimental autoimmune encepha-
lomyelitis and autoimmune uveitis, IVIg is thought to reduce 
the production of  interleukin-2 and  interferon-γ by  T-cells 
[47, 55], preventing the development of disease. This is also 
thought to be one of the major effector mechanisms in the 
treatment  of  GBS  and  CIDP.  IVIg  preparations  have  also 
been  shown  to  contain  antibodies  against  CD4  cells  [28], 
soluble HLA class I and II molecules [21], chemokine recep-
tor, CCR-5 [8] and T-cell receptor β chain [40]. The possibil-
ity  that  therapeutic  doses  of  immunoglobulins  restores  the 
balance  between  Th1  and  Th2  cells  has  been  the  main  
rationale for several IVIg trials in multiple sclerosis [31].  
3. Effect of IVIg on the Complement System 
  The heat-labile component of serum that augmented its 
bactericidal properties is one of the main pathogenic path-
ways  involved  in  antibody-mediated  autoimmune diseases. 
The formation of immune  complexes activate  the classical 
complement  cascade  resulting  in  the  production  of  mem-
brane attack complexes (MAC) which are thought to induce 
organ  specific  tissue  damage  in  a  variety  of  autoimmune 
diseases, like myasthenia gravis, lupus nephritis and GBS.  
  The anti-inflammatory activity of IVIg is at least partly 
mediated by its ability to prevent the formation of MAC and 
subsequent  tissue  destruction.  Antibodies  against  several 
components of the classical complement pathway have been 
identified in IVIg. They include antibodies against C1 [43], 
C3a [6], C3b or C4 [20]. In addition, high doses of IVIg are 
thought to enhance the degradation of C3b [38]. In-vitro in-
crease of complement uptake has been demonstrated in GBS 
and MG [5] and complement is thought to be important in 
GBS and its variant, Miller-Fisher syndrome [22, 23, 74], in 
which complement therapies are under investigation [22, 23]. 
4. IVIg Mediated Fc Receptor Blockade on Macrophages 
  FcγR receptors on the surface of macrophages can medi-
ate inflammatory pathways by activating (FcγRI or FcγRIII) 
or  inhibiting  (FcγRII)  different  receptors  [31].  IVIg  may 
inhibit  the  FcγRI  or  FcγRIII  receptors  or  upregulate  the 
FcγRII receptors [14]. In idiopathic thrombocytopenic pur-
pura (ITP), IVIg is thought to inhibit platelet phagocytosis 
through the FcγRII receptor [54]. In GBS and CIDP, inhibi-
tion  of  macrophage  function  reduces  the  phagocytosis  of 
antigen-presenting cells and antibody-mediated cellular cyto-
toxicity, thus inhibiting macrophage-mediated demyelination 
[13]. Similarly an increase in ratio of FcγRII/FcγRIII recep-
tors on monocytes have been demonstrated a week after IVIg 
administration in patients with CIDP and MMN who were 
beginning to improve [11].  
5. Effect of IVIg on Cytokines 
  Cytokines are proteins or glycoproteins involved in the 
signalling  process  during  a  variety  of  immune  reactions. 
Dysregulation of the cytokine system has been proposed as 
one of the mechanisms of autoimmunity.  
  IVIg reduces the levels of circulating IL-1β in patients 
with GBS [57] and Kawasaki disease [37]. Thousand fold 
increase in the levels of IL-1 receptor antagonist have been 
shown after IVIg therapy [3]. However, cytokine modulation 
is unlikely to be the major mechanism of action of immuno-
globulins,  since  IVIg  remains  functionally  active  in  mice 
strains deficient in IL-1R, IL-4, IL-10, IFN-γR, IL-12β and 
TNF-α [12]. TNF-α mediated cytotoxicity is also inhibited 
by IVIg [59]. 
6. Effect of IVIg in Modulating Cell Migration 
  Leukocyte migration across biological barriers has been 
suggested to be an important mechanism in the causation of 
organ  specific  autoimmune  diseases.  IVIg  is  thought  to 
modulate endothelial cell function by interacting with inter-
cellular adhesion molecules (ICAM) [75]. A significant re-
duction in expression of ICAM-1 was seen in 8 out of 10 
patients with MMN and  CIDP, during the first week after 
infusion of IVIg [11].  
  Other possible mechanisms by which IVIg modulate cell 
migration  include  the  presence  of  antibodies  against  in-
tegrins  [34]  and  the  argine-glycine-aspargine  (RGD)  cell 
adhesion motifs [71]. Inhibition of the chemokine (C-C mo-
tif) receptor-5 (CCR-5) by IVIg prevents the entry of HIV 
into its target cells [8].  
7. Effect of IVIg on Superantigens 
  Superantigens  like  bacterial  enterotoxins  and  viruses 
stimulate the Vβ chains of the T-cell receptor triggering the 
production of cytokines and breaking immune tolerance. The 
role of IVIG against the β-chains of the T-cell receptor [40] 
may thus be relevant in the influence of relapses triggered by 
infections in MG and CIDP [14].  
8. Other Mechanisms of Action of IVIg 
  In toxic epidermal necrolysis, apoptosis of keratinocytes 
is prevented by blocking CD95, the Fas death receptor [73].  
  There is considerable variation  in  the sugar moiety at-
tached to the aspargine 297 (N297) residue of the Fc portion 
of IgG. It has been suggested that sialic acid rich IgG levels 
are reduced in acute phases of several autoimmune disease 
models. Infusion of IVIg, which is pooled from several do-
nors, may restore the level of sialic acid-rich IgG, thus in-
ducing an anti-inflammatory action, possibly through novel 
receptors in regulatory macrophages. [30, 44, 45].  
  In  addition  to  the  above  mentioned  immune  mediated 
effects,  whether  IVIg  has  a  direct  effect  on  remyelination 
[68] in diseases like GBS and CIDP is not very clearly un-
derstood.  
MECHANISMS  OF  SIDE-EFFECTS  PRODUCED  BY 
IVIG 
  Generally the side-effects of IVIg are usually minor oc-
curring in less than 1 in 10 patients. Myalgia, chills or chest 
pain may occur in the first hour of infusion, which can be 
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at a slower rate. Fatigue, nausea and headache may occur for 
up to 24 hours. The exact pathogenesis of these side-effects 
are not clearly understood, but activation of the complement 
pathway by aggregated immunoglobulins may be partly re-
sponsible. This may also be partly responsible for the infre-
quent side-effect of aseptic meningitis.  
  Increase  in  serum  viscosity  produced  by  IVIg  leads  to 
increased risk of thrombo-embolic events, especially in pre-
existing hyperviscosity syndromes like high cholesterol lev-
els,  hypergammaglobulinemia  or  cryoglobulinemia.  Simi-
larly, rate of infusion has to be slowed in patients with fluid 
overload like congestive cardiac failure. Although theoreti-
cally possible, hemolysis due to anti-A/B IgG blood group 
antibodies is almost never seen in clinical practice.  
  Severe  anaphylactic  reactions  are  fortunately  rare,  but 
cause a potential problem in selective IgA deficiency, which 
occurs in 1:1000 patients. These patients may have anti-IgA 
antibodies, which cross-react with the small IgA content in 
the  infused IVIg, causing  macromolecular  complexes. Un-
less in an emergency situation, it is a good practice to check 
the immunoglobulin levels prior to commencement of IVIg 
therapy. 
Subcutaneous Immunoglobulin (SCIg) as an Alternative 
to IVIg 
  Side  effects  of  IVIg  are  likely  to  be  secondary  to  an  
allergic reaction to a large quantity of foreign protein. The 
administration  of  Ig  by  subcutaneous  route  (usually  by  a 
small portable pump at home) has been used mainly to avoid 
these systemic side effects, but also to reduce the cost and  
to  maintain  higher  trough  levels.  SCIg  has  generally  been 
employed in the treatment of primary immunodeficiencies. 
Some studies even suggest safer administration of SCIg in 
patients with IgA sensitisation and in pregnancy. SCIg has 
been shown to be effective in small series of patients with 
MMN[24] and CIDP [35]. However, SCIg has to be admin-
istered more frequently, can have local skin reactions and is 
contraindicated  in  patients  on  anticoagulant  therapy  and 
those with bleeding disorders and thrombocytopenia. Further 
large trials are required before this can be used as standard 
practice in inflammatory neuropathies.  
Most Plausible Mechanisms of Action of IVIg in Inflammatory Neu-
ropathies 
1.  Anti-idiotype antibody production 
2.  Inhibition of complement pathway 
3.  Fc receptor modulation on macrophages and other effector cells 
4.  Suppression of pathogenic cytokines  
5.  Effects on cell migration by modulation of adhesion molecules 
6.  T-cell modulation 
7.  Direct effect on remyelination 
 
SUMMARY 
  Several immune components are likely to be important in 
the pathogenesis of GBS, CIDP and MMN. Demyelination 
in GBS and CIDP may happen along the course of the nerve, 
which requires a breakdown of blood-nerve barrier, where T-
cells may be important for the pathophysiology. Demyelina-
tion  also  occurs  distally  in  the  intramuscular  part  of  the 
nerve, where the barrier is absent, possibly mediated by hu-
moral factors. Early in  the disease course in GBS,  T-cells 
may play an important role in pathogenesis as evidenced by 
increase in soluble IL-2 receptors with a reduction in IL-2. 
Increased levels of IL-6, TNF-α and IFN-γ are found in se-
rum and CSF with increasing severity of the disease. Evi-
dence of peripheral T-cell activation in the form of increased 
expression of HLA-DR, membrane-bound IL-2 receptor and 
transferrin  receptor  are  also  noticed  during  the  course  of 
GBS. 
  The presence of auto-antibodies in several patients with 
GBS (plus its variants) and MMN, suggests that the effect on 
B-cells and the complement pathway might play a significant 
role in the therapeutic efficacy of IVIg in these conditions. 
However not all patients have a clearly detectable antibody 
and hence T-cells and cytokines are thought to have a sig-
nificant pathogenic role, as discussed earlier. 
  In conclusion, there are several possible mechanisms of 
action of IVIg, none of which has been conclusively proven 
to be the dominating pathway. The main mechanisms which 
are likely to be responsible in inflammatory neuropathies are 
summarised  in  Box  1.  It  is  possible  that  combinations  of 
different  mechanisms  are  involved  in  several  autoimmune 
neurological diseases where IVIg remains a highly effective 
therapy.  
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